ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: diabetes

Secrets & Pearls of Rheumatology at ACR Convergence 2025

Mithu Maheswaranathan, MD  |  

Two clinical diagnosticians presented their pearls of wisdom for clinical rheumatologists to take forward when managing patients from the clinics to the hospital wards.

New Rheumatoid Arthritis Risk Stratification Criteria Released

  |  

New EULAR/ACR criteria help stratify RA risk in patients with arthralgia. Learn how these criteria guide earlier interventions & improve trial rigor.

Lupus Nephritis: A Serious Manifestation of Systemic Lupus Erythematosus

Graciela S. Alarcón, MD, MPH, MACR  |  

In this review, some of the many abstracts on research into lupus nephritis presented at ACR Convergence 2025 are highlighted. The abstracts selected demonstrate the advances made on the early recognition of the condition, as well as offering some hope in terms of achieving better outcomes.

Let’s Discuss Part 2: More Insights from the ACR Convergence 2025 Review Course

  |  

The Review Course at ACR Convergence 2025 provided a comprehensive update for practitioners. Highlights from the sections on cutaneous manifestations of rheumatic diseases, gout, macrophage activation syndrome and vasculitis.

Gout & Cardiometabolic Co-Morbidities

  |  

ACR Convergence 2025 experts explore gout’s deep ties to MetS, insulin resistance and cardiovascular mortality, weighing new data on colchicine, febuxostat and SGLT2 inhibitors.

Let’s Discuss: Insights from the ACR Convergence 2025 Review Course

  |  

The Review Course at ACR Convergence 2025 provided a comprehensive update for practitioners. Highlights from the sections on SLE and lupus nephritis, inflammatory brain diseases, drug management of rheumatic diseases and mimics of inflammatory myopathies.

Study: Reducing Cardiovascular Risks Helps Lupus Patients

Deborah Levenson  |  

Long-term remission & control of CVD risk factors can reduce the risk of atherosclerosis in lupus; triple APL positivity raises the risk of CVD, study finds.